{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:56Z","timestamp":1793830496129,"version":"4.6.1"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2021,11,27]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Clinicians and policymakers are promoting widespread use of home technology including spirometry to detect disease progression for patients with interstitial lung disease (ILD); the COVID-19 pandemic has accelerated this. Data collating clinicians\u2019 views on the potential utility of telehealth in ILD are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This survey investigated clinicians\u2019 opinions about contemporary methods and practices used to monitor disease progression in patients with ILD using telehealth.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinicians were invited to participate in a cross-sectional survey (SurveyMonkey) of 13 questions designed by an expert panel. Telehealth was defined as home monitoring of symptoms and physiological parameters with regular automatic transmission of data from the patient\u2019s home to the clinician. Data are presented as percentages of respondents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 207 clinicians from 23 countries participated in the survey. A minority (81, 39%) reported using telehealth. 50% (n=41) of these respondents completed a further question about the effectiveness of telehealth. A majority of respondents (32, 70%) rated it to be quite or more effective than face-to-face visit. There were a greater number of respondents using telehealth from Europe (94, 45%) than Asia (51, 25%) and America (24%). Clinicians reported the most useful telehealth monitoring technologies as smartphone apps (59%) and wearable sensors (30%). Telehealth was most frequently used for monitoring disease progression (70%), quality of life (63%), medication use (63%) and reducing the need for in-person visits (63%). Clinicians most often monitored symptoms (93%), oxygen saturation (74%) and physical activity (72%). The equipment perceived to be most effective were spirometers (43%) and pulse oximeters (33%). The primary barriers to clinicians\u2019 participation in telehealth were organisational structure (80%), technical challenges (63%) and lack of time and\/or workload (63%). Clinicians considered patients\u2019 barriers to participation might include lack of awareness (76%), lack of knowledge using smartphones (60%) and lack of confidence in telehealth (56%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The ILD clinicians completing this survey who used telehealth to monitor patients (n=81) supported its\u2019 clinical utility. Our findings emphasise the need for robust research in telehealth as a mode for the delivery of cost-effective healthcare services in ILD and highlight the need to assess patients\u2019 perspectives to improve telehealth utility in patients with ILD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2021-001088","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T08:50:40Z","timestamp":1640854240000},"page":"e001088","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-5708","authenticated-orcid":false,"given":"Malik","family":"Althobiani","sequence":"first","affiliation":[{"name":"UCL Respiratory, University College London, London, UK"},{"name":"Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1795-5092","authenticated-orcid":false,"given":"Jaber S","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Hurst","sequence":"additional","affiliation":[{"name":"UCL Respiratory, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Russell","sequence":"additional","affiliation":[{"name":"College of Medicine and Health, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Porter","sequence":"additional","affiliation":[{"name":"UCL Respiratory, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"2025083110412988000_8.1.e001088.1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110412988000_8.1.e001088.2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S2213-2600(20)30452-5","article-title":"Home monitoring for patients with ILD and the COVID-19 pandemic","volume":"8","author":"Nakshbandi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025083110412988000_8.1.e001088.3","unstructured":"Foundation BL . Coronavirus and COVID-19, 2020. Available: https:\/\/www.blf.org.uk\/support-for-you\/coronavirus\/what-is-social-shielding"},{"key":"2025083110412988000_8.1.e001088.4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.chest.2020.04.019","article-title":"Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic","volume":"158","author":"Wong","year":"2020","journal-title":"Chest"},{"key":"2025083110412988000_8.1.e001088.5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025083110412988000_8.1.e001088.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-018-0810-3","article-title":"A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers","volume":"19","author":"Moor","year":"2018","journal-title":"Respir Res"},{"key":"2025083110412988000_8.1.e001088.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02406-2016"},{"key":"2025083110412988000_8.1.e001088.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02089-2017"},{"key":"2025083110412988000_8.1.e001088.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01518-2020"},{"key":"2025083110412988000_8.1.e001088.10","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1093\/rheumatology\/keaa607","article-title":"Feasibility of online home spirometry in systemic sclerosis\u2013associated interstitial lung disease: a pilot study","volume":"60","author":"Moor","year":"2021","journal-title":"Rheumatology"},{"key":"2025083110412988000_8.1.e001088.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01524-8","article-title":"Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study","volume":"21","author":"Veit","year":"2020","journal-title":"Respir Res"},{"key":"2025083110412988000_8.1.e001088.12","doi-asserted-by":"crossref","DOI":"10.4103\/jpi.jpi_20_19","article-title":"Role of telemedicine in multidisciplinary team meetings","volume":"10","author":"Aghdam","year":"2019","journal-title":"J Pathol Inform"},{"key":"2025083110412988000_8.1.e001088.13","first-page":"314","article-title":"[Telemedicine: perspectives and multidisciplinary approach]","volume":"130","author":"Demartines","year":"2000","journal-title":"Schweiz Med Wochenschr"},{"key":"2025083110412988000_8.1.e001088.14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-10-52"},{"key":"2025083110412988000_8.1.e001088.15","doi-asserted-by":"crossref","DOI":"10.2196\/17597","article-title":"Once daily versus overnight and symptom versus physiological monitoring to detect exacerbations of chronic obstructive pulmonary disease: pilot randomized controlled trial","volume":"8","author":"Al Rajeh","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"2025083110412988000_8.1.e001088.16","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.7207","article-title":"Exacerbations in chronic obstructive pulmonary disease: identification and prediction using a digital health system","volume":"19","author":"Shah","year":"2017","journal-title":"J Med Internet Res"},{"key":"2025083110412988000_8.1.e001088.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000817"},{"key":"2025083110412988000_8.1.e001088.18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","article-title":"Home monitoring in patients with idiopathic pulmonary fibrosis. A randomized controlled trial","volume":"202","author":"Moor","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110412988000_8.1.e001088.19","doi-asserted-by":"crossref","DOI":"10.3390\/jpm9020023","article-title":"Feasibility of a comprehensive home monitoring program for sarcoidosis","volume":"9","author":"Moor","year":"2019","journal-title":"J Pers Med"},{"key":"2025083110412988000_8.1.e001088.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02508-2017"},{"key":"2025083110412988000_8.1.e001088.21","unstructured":"Moor K , Johannson KAM , Maher TM . eHealth and Home-Monitoring of patients with interstitial lung diseases; worldwide experiences and perspectives. TP27 TP027 diffuse parenchymal lung disease: patient characteristics and outcomes."},{"key":"2025083110412988000_8.1.e001088.22","article-title":"Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial","volume":"54","author":"Maher","year":"2019","journal-title":"European Respiratory Journal"},{"key":"2025083110412988000_8.1.e001088.23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1513\/AnnalsATS.201904-335RL","article-title":"Mobile health monitoring in patients with idiopathic pulmonary fibrosis","volume":"16","author":"Marcoux","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110412988000_8.1.e001088.24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000446607","article-title":"Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis","volume":"91","author":"Bahmer","year":"2016","journal-title":"Respiration"},{"key":"2025083110412988000_8.1.e001088.25","doi-asserted-by":"crossref","unstructured":"Althobiani MA , Evans RA , Alqahtani JS , et al . Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Res 2021:00441-2021\u20132021.doi:10.1183\/23120541.00441-2021","DOI":"10.1183\/23120541.00441-2021"},{"key":"2025083110412988000_8.1.e001088.26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/resp.12320","article-title":"Transbronchial cryobiopsy in the diagnosis of interstitial lung disease: a cool new approach","volume":"19","author":"Mikolasch","year":"2014","journal-title":"Respirology"},{"key":"2025083110412988000_8.1.e001088.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025083110412988000_8.1.e001088.28","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-2-146"},{"key":"2025083110412988000_8.1.e001088.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025083110412988000_8.1.e001088.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2025083110412988000_8.1.e001088.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2025083110412988000_8.1.e001088.32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00259-017-3917-8","article-title":"Pulmonary \n                  18\n               F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)","volume":"45","author":"Win","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025083110412988000_8.1.e001088.33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(17)30122-4","article-title":"Clinical trial research in focus: why do so many clinical trials fail in IPF?","volume":"5","author":"Spagnolo","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025083110412988000_8.1.e001088.34","article-title":"Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry: the Diva study","volume":"54","author":"Moor","year":"2019","journal-title":"European Respiratory Journal"},{"key":"2025083110412988000_8.1.e001088.35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025083110412988000_8.1.e001088.36","doi-asserted-by":"crossref","DOI":"10.2196\/16158","article-title":"Use of the patientMpower APP with home-based spirometry to monitor the symptoms and impact of fibrotic lung conditions: longitudinal observational study","volume":"8","author":"Edwards","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"2025083110412988000_8.1.e001088.37","doi-asserted-by":"crossref","DOI":"10.2196\/28873","article-title":"Remote assessment of lung disease and impact on physical and mental health (RALPMH): protocol for a prospective observational study","volume":"10","author":"Ranjan","year":"2021","journal-title":"JMIR Res Protoc"},{"key":"2025083110412988000_8.1.e001088.38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.resinv.2019.12.010","article-title":"Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis","volume":"58","author":"Takei","year":"2020","journal-title":"Respir Investig"},{"key":"2025083110412988000_8.1.e001088.39","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00405-2021"},{"key":"2025083110412988000_8.1.e001088.40","doi-asserted-by":"crossref","DOI":"10.2196\/26336","article-title":"Us physicians' perspective on the sudden shift to telehealth: survey study","volume":"8","author":"Walia","year":"2021","journal-title":"JMIR Hum Factors"},{"key":"2025083110412988000_8.1.e001088.41","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030097","article-title":"Benefit of wearing an activity Tracker in sarcoidosis","volume":"10","author":"Drent","year":"2020","journal-title":"J Pers Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2021-001088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:41:42Z","timestamp":1756662102000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2021-001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,30]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjresp-2021-001088"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2021-001088","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}